Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

brief summary

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.